Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Happy to share that this collaborative work led by our colleagues at the CNIO – Spanish National Cancer Research Centre has just been published in PNAS.
The paper shows that triple inhibition KRAS^hi + afatinib (EGFRi) + a STAT3 PROTAC (SD36), achieves complete and durable regression of pancreatic tumors in PDO, PDX, and murine models, with no relapse for over 200 days and no detectable toxicity.
A key conceptual advance: overcoming therapeutic resistance in PDAC requires coordinated inhibition of KRAS downstream (RAF1), upstream (EGFR), and parallel survival pathways (STAT3).
I’m very glad that our team in Marseille could contribute to this international effort, and grateful to the CNIO group for leading such impactful work.
Congratulations to Vasiliki Liaki, Mariano Barbacid, Carmen Guerra, and all co-authors for this remarkable work.”
Title: A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
Authors: Vasiliki Liaki, Sara Barrambana, Myrto Kostopoulou, Carmen G. Lechuga, Elena Zamorano-Dominguez, Domingo Acosta, Lucia Morales-Cacho, Ruth Álvarez, Pian Sun, Blanca Rosas-Perez, Rebeca Barrero, Silvia Jiménez-Parrado, Alejandra López-García, Marta San Roman, Juan Carlos López-Gil, Matthias Drosten, Bruno Sainz Jr., Monica Musteanu, Eduardo Caleiras, Nelson Dusetti, Valeria Poli, Francisco Sánchez-Bueno, Carmen Guerra, Mariano Barbacid
Read the Full Article on PNAS
More posts featuring Nelson Dusetti.